Cushing's syndrome: Development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type

Journal of Medicinal Chemistry

Volumn 56, Issue 15, 2013, Pages 6022-6032

  Emmerich, Juliette ^a   Hu, Qingzhong ^a   Hanke, Nina ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 PHENYLPYRIDIN 3 YL)ETHANOL; 2 BROMO 5 (BROMOMETHYL)PYRIDINE; 2 PHENYL 5 (PYRIDIN 3 YLMETHYL)PYRIDINE; 2 PHENYL 5 (PYRIDIN 4 YLMETHYL)PYRIDINE; 2 PHENYL 5 [[5 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL]PYRIDINE; 4 [(1H IMIDAZOL 1 YL)METHYL) 1 PHENYLISOQUINOLINE; 4 [(6 PHENYLPYRIDIN 3 YL)METHYL]ISOQUINOLINE; 5 (BROMOMETHYL) 2 PHENYLPYRIDINE; 5 [(1H IMIDAZOL 1 YL)(PHENYL)METHYL] 2 PHENYLPYRIDINE; 5 [(4 METHYLPYRIDIN 3 YL)METHYL] 2 PHENYLPYRIDINE; 5 [(5 FLUOROPYRIDIN 3 YL)METHYL] 2 PHENYLPYRIDINE; 5 [(5 METHOXYPYRIDIN 3 YL)METHYL] 2 PHENYLPYRIDINE; 5 [(5 METHYLPYRIDIN 3 YL)METHYL] 2 PHENYLPYRIDINE; 5 [(6 PHENYLPYRIDIN 3 YL)METHYL]NICOTINAMIDE; 5 [(6 PHENYLPYRIDIN 3 YL)METHYL]PYRIDIN 3 OL; 5 [1 (1H IMIDAZOL 1 YL) 2 METHYLPROPYL] 2 PHENYLPYRIDINE; 5 [1 (1H IMIDAZOL 1 YL)ETHYL] 2 (NAPHTHALEN 1 YL)PYRIDINE; 5 [1 (1H IMIDAZOL 1 YL)ETHYL] 2 (THIOPHEN 3 YL)PYRIDINE; 5 [1 (1H IMIDAZOL 1 YL)ETHYL] 2 PHENYLPYRIDINE; 5 [1 (1H IMIDAZOL 1 YL)PROPYL] 2 PHENYLPYRIDINE; 5 [CYCLOPROPYL(1H IMIDAZOL 1 YL)METHYL] 2 (NAPHTHALEN 1 YL)PYRIDINE; 5 [CYCLOPROPYL(1H IMIDAZOL 1 YL)METHYL] 2 (THIOPHEN 3 YL)PYRIDINE; 5 [CYCLOPROPYL(1H IMIDAZOL 1 YL)METHYL] 2 PHENYLPYRIDINE; 5 [FURAN 2 YL(1H IMIDAZOL 1 YL)METHYL] 2 PHENYLPYRIDINE; 5 METHYL 2 PHENYLPYRIDINE; 6 BROMONICOTINALDEHYDE; 6 PHENYLNICOTINALDEHYDE; ENZYME INHIBITOR; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; CYTOTOXICITY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RAT;

ALDOSTERONE SYNTHASE; ANIMALS; CELL LINE; CRICETINAE; CUSHING SYNDROME; HUMANS; LIVER; MODELS, MOLECULAR; PYRIDINES; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; STEROID 11-BETA-HYDROXYLASE;

EID: 84880174933     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400240r     Document Type: Article

References (29)

1. Fleseriu, M.; Petersenn, S. Medical management of Cushing's disease: What is the future? Pituitary 2012, 15, 330-341
2. Dang, C. N.; Trainer, P. Pharmacological management of Cushing's syndrome: An update Arq. Bras. Endocrinol. Metab. 2007, 51, 1339-1348
3. Morton, N. M. Obesity and corticosteroids: 11β-hydroxy-steroid type 1 as a cause and therapeutic target in metabolic disease Mol. Cell. Endocrinol. 2010, 316, 154-164
4. White, P. C.; Curnow, K. M.; Pascoe, L. Disorders of steroid 11β-hydroxylase isozymes Endocr. Rev. 1994, 15, 421-438
5. Gower, D. B. Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications J. Steroid Biochem. 1974, 5, 501-523
6. Mornet, E.; Dupont, J.; Vitek, A.; White, P. C. Characterization of two genes encoding human steroid 11β-hydroxylase [P-450(11)β] J. Biol. Chem. 1989, 264, 20961-20967
7. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
8. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
9. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
10. Lucas, S.; Negri, M.; Heim, R.; Zimmer, C.; Hartmann, R. W. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one derivatives J. Med. Chem. 2011, 54, 2307-2319
11. Hille, U. E.; Zimmer, C.; Haupenthal, J.; Hartmann, R. W. Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases ACS Med. Chem. Lett. 2011, 2, 559-564
12. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases ACS Med. Chem. Lett. 2011, 2, 2-6
13. Yin, L.; Lucas, S.; Maurer, F.; Kazmaier, U.; Hu, Q.; Hartmann, R. W. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1- ij ]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome J. Med. Chem. 2012, 55, 6629-6633
14. Schenkman, J. B.; Sligar, S. G.; Cinti, D. L. Substrate interaction with cytochrome P-450 Pharmacol. Ther. 1981, 12, 43-71
15. Yin, L.; Hu, Q.; Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks J. Med. Chem. 2013, 56, 460-470
16. Roumen, L.; Sanders, M. P.; Pieterse, K.; Hilbers, P. A.; Plate, R.; Custers, E.; de Gooyer, M.; Smits, J. F.; Beugels, I.; Emmen, J.; Ottenheijm, H. C.; Leysen, D.; Hermans, J. J. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics J. Comput.-Aided Mol. Des. 2007, 21, 455-471
17. Tosco, P.; Balle, T. Open3DQSAR: a new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields J. Mol. Model. 2011, 17, 201-208
18. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part II: Core rigidification and influence of substituents at the methylene bridge Bioorg. Med. Chem. 2008, 16, 7715-7727
19. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
20. Lézé, M.-P.; Le Borgne, M.; Pinson, P.; Palusczak, A.; Duflos, M.; Le Bauta, G.; Hartmann, R. W. Synthesis and biological evaluation of 5-[(aryl)(1 H -imidazol-1-yl)methyl]-1 H -indoles: potent and selective aromatase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 1134-1137
21. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 2007, 50, 3420-3422
22. Stefanachi, A.; Favia, A. D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; Hartmann, R. W.; Carotti, A. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase J. Med. Chem. 2011, 54, 1613-1625
23. Gobbi, S.; Hu, Q.; Negri, M.; Zimmer, C.; Belluti, F.; Rampa, A.; Hartmann, R. W.; Bisi, A. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11beta-hydroxylase inhibition J. Med. Chem. 2013, 56, 1723-1729
24. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 chinese hamster cells Endocr. Res. 1995, 21, 443-448
25. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179
26. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C(17,20)- lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63
27. Hutschenreuter, T. U.; Ehmer, P. E.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 Inhibitors as potential metabolites and evaluation of their activity by a noncellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32
28. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369
29. Haupenthal, J.; Baehr, C.; Zeuzem, S.; Piiper, A. RNAse A-like enzymes in serum inhibit the antineoplastic activity of siRNA targeting polo-like kinase 1 Int. J. Cancer 2007, 121, 206-210